Iatrogenic Cushing's Syndrome in an HIV-Infected patient treated with Inhaled corticosteroids (fluticasone propionate) and low dose ritonavir enhanced PI containing regimen

Journal of Infection

Volumn 44, Issue 3, 2002, Pages 194-195

  Clevenbergh, P ^a   Corcostegui, M ^a   Gerard D ^a   Hieronimus, S ^a   Mondain, V ^a   Chichmanian, R M ^a   Sadoul, J L ^a   Dellamonica, P ^a  

^a UNIVERSITY HOSPITAL OF NICE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; BUDESONIDE; CORTICOSTEROID; CORTICOTROPIN; CYTOCHROME P450; CYTOCHROME P450 INHIBITOR; DIDANOSINE; EFAVIRENZ; FLUTICASONE PROPIONATE; HYDROCORTISONE; LAMIVUDINE; PROTEINASE INHIBITOR; RITONAVIR; SALMETEROL; STAVUDINE; TERBUTALINE;

ACNE; ADULT; ARTICLE; ASTHMA; CANDIDA; CASE REPORT; CLINICAL EXAMINATION; CLINICAL FEATURE; CUSHING SYNDROME; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG WITHDRAWAL; ENZYME INHIBITION; ESOPHAGITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERADRENOCORTICISM; IATROGENIC DISEASE; LOW DRUG DOSE; MALE; MOON FACE; PHYSICIAN; WEIGHT GAIN;

EID: 0036556381     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1053/jinf.2001.0928     Document Type: Article

References (10)

1. Malaty LI, Kuper JJ. Drug interactions of HIV protease inhibitors. Drug Saf 1999; 20: 147-169.
2. Hsu A, Granneman GR, Cao G et al. Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers. Antimicrob Agents Chemother 1998; 42: 784-791.
3. Hsu A, Granneman GR, Cao G et al. Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir. Clin Pharmacol Ther 1998; 63: 453-464.
4. Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 2000; 38: 41-57.
5. Mollmann H, Wagner M, Meibohm B et al. Pharmacokinetic and pharmacodynamic evaluation of fluticasone propionate after inhaled administration. Eur J Clin Pharmacol 1998; 53: 459-467.
6. Li JT, Ford LB, Chervinsky P et al. Fluticasone propionate powder and lack of clinically significant effects on hypothalamic-pituitary-adrenal axis and bone mineral density over 2 yeras in adults with mild asthma. J Allergy Clin Immunol 1999; 103:1062-1068.
7. Harding SM. The Human pharmacology of fluticasone propionate. Respir Med 1990; 84: 25-29.
8. Brus R. Effects of high-dose inhaled corticosteroids on plasma cortisol concentrations in healthy adults. Arch Intern Med 1999: 159: 1903-1908.
9. Chen F, Kearney T, Robinson S, Daley-Yates PT, Waldron S. Churchill DR. Cushing's syndrome and severe adrenal suppression in patients treated with ritonavir and inhaled nasal fluticasone. Sex Transm Infect 1999; 75: 274.
10. Hillebrand-Haverkort ME, Prummel MF, ten Veen JH. Ritonavir-induced Cushing's syndrome in a patient treated with nasal fluticasone. AIDS 1999; 13: 1803.